MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.510
-0.030
-1.18%
After Hours: 2.520 +0.01 +0.40% 19:58 06/24 EDT
OPEN
2.580
PREV CLOSE
2.540
HIGH
2.670
LOW
2.420
VOLUME
9.01M
TURNOVER
0
52 WEEK HIGH
17.65
52 WEEK LOW
1.670
MARKET CAP
541.31M
P/E (TTM)
-7.2209
1D
5D
1M
3M
1Y
5Y
Ocugen's efforts to bring Covid-19 vaccine Covaxin to U.S. boosted by positive study results in children
The Chester County company is working with the India-based developer of Covaxin to bring the Covid-19 vaccine to North America.
American City Business Journals · 5d ago
Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years
Benzinga · 5d ago
BRIEF-Ocugen Announces Publication Of Positive Results Of Covid-19 Vaccine Trial For Children 2-18 In The Lancet Infectious Diseases
reuters.com · 5d ago
Ocugen, Bharat Biotech COVID vaccine shows better safety/efficacy in kids compared to adults
Ocugen (NASDAQ:OCGN) said interim data from phase 2/3 trial of Covaxin, developed by India's Bharat Biotech, was published in a journal and showed that the COVID-19 vaccine showed efficacy and superior
Seekingalpha · 5d ago
Ocugen Announces Publication Of Results Of COVID-19 Vaccine Trial For Children 2-18 In The Lancet Infectious Diseases
Ocugen’s partner Bharat Biotech’s Phase 2/3 study of COVAXIN™ (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults Ocugen has North American
Benzinga · 5d ago
Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
Ocugen’s partner Bharat Biotech’s Phase 2/3 study of COVAXIN™ (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults Ocugen has North American commercialization rights for COVAXIN™ MALVERN, Pa., June 21, 2022 (GLOBE...
GlobeNewswire · 5d ago
Roth Capital Reinstates Ocugen at Buy with $8 Price Target
MT Newswires · 06/15 11:20
Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’
MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Bus...
GlobeNewswire · 06/14 11:00
More
No Data
Learn about the latest financial forecast of OCGN. Analyze the recent business situations of Ocugen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
80.00%Buy
20.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OCGN stock price target is 7.60 with a high estimate of 15.00 and a low estimate of 3.500.
High15.00
Average7.60
Low3.500
Current 2.510
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Q2 2021
Q3 2021
Q4 2021
  • 0
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 134
Institutional Holdings: 90.25M
% Owned: 41.85%
Shares Outstanding: 215.66M
TypeInstitutionsShares
Increased
39
25.01M
New
21
549.97K
Decreased
33
3.52M
Sold Out
24
1.53M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Chairman/Chief Executive Officer/Director
Shankar Musunuri
Senior Vice President - Finance/Chief Accounting Officer
Jessica Crespo
Senior Vice President
Nirdosh Jagota
Senior Vice President
Vijay Tammara
Director
Marna Whittington
Independent Director
Kirsten Castillo
Independent Director
Prabhavathi Fernandes
Independent Director
Uday Kompella
Independent Director
Ramesh Kumar
Independent Director
Junge Zhang
No Data
No Data
About OCGN
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies to cure blindness diseases and developing vaccine for COVID-19. The Company's technology pipeline includes: COVID-19 Vaccine (0.5), Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. COVID-19 Vaccine candidate is focused on developing, manufacturing and commercializing COVAXIN for the prevention of COVID-19 in humans in the Ocugen Covaxin Territory. COVAXIN is a whole-virion inactivated COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus. The Modifier Gene Therapy platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). It is developing OCU200, a biologic product candidate to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet AMD. OCU400, its first product candidate being developed with its modifier gene therapy platform.

Webull offers kinds of Ocugen Inc stock information, including NASDAQ:OCGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCGN stock methods without spending real money on the virtual paper trading platform.